Jacobs Levy Equity Management Inc. Has $4.11 Million Holdings in Codexis, Inc. (NASDAQ:CDXS)

Jacobs Levy Equity Management Inc. lessened its holdings in shares of Codexis, Inc. (NASDAQ:CDXS) by 3.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 860,955 shares of the biotechnology company’s stock after selling 34,740 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in Codexis were worth $4,107,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Summit Investment Advisors Inc. increased its position in Codexis by 81.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company’s stock worth $40,000 after buying an additional 3,783 shares during the last quarter. Fiduciary Trust Co bought a new position in shares of Codexis during the fourth quarter worth approximately $65,000. Group One Trading LLC bought a new position in shares of Codexis during the fourth quarter worth approximately $73,000. Kingswood Wealth Advisors LLC bought a new position in shares of Codexis during the fourth quarter worth approximately $79,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Codexis during the fourth quarter worth approximately $82,000. Institutional investors and hedge funds own 78.54% of the company’s stock.

Codexis Price Performance

Shares of NASDAQ CDXS opened at $2.47 on Thursday. The firm has a market cap of $204.63 million, a P/E ratio of -2.84 and a beta of 2.56. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. Codexis, Inc. has a 1-year low of $1.90 and a 1-year high of $6.08. The business’s 50 day moving average is $2.45 and its 200-day moving average is $3.74.

Codexis (NASDAQ:CDXS) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). The firm had revenue of $7.54 million for the quarter, compared to the consensus estimate of $10.38 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. Equities research analysts predict that Codexis, Inc. will post -0.77 earnings per share for the current year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.